-
Mashup Score: 0Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas - 4 year(s) ago
Isocitrate dehydrogenase-mutant low-grade gliomas (IDHmut-LGG) grow slowly but frequently undergo malignant transformation, which eventually leads to premature death. Chemotherapy and radiotherapy treatments prolong survival, but can also induce genetic (or epigenetic) alterations involved in transformation. Here, we developed a mathematical model of tumor progression based on serial tumor volume…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Recent Advances in Pediatric Cancer Research - 4 year(s) ago
Over the past few years, the field of pediatric cancer has experienced a shift in momentum, and this has led to new and exciting findings that have relevance beyond pediatric malignancies. Here we present the current status of key aspects of pediatric cancer research. We have focused on genetic and epigenetic drivers of disease, cellular origins of different pediatric cancers, disease models, the…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @TroyMcEachron: Our review article "Recent Advances in Pediatric Cancer Research" is now available online! https://t.co/L9UWaJU44i Than…
-
-
Mashup Score: 2Translating the Science of Cancer Dormancy to the Clinic - 4 year(s) ago
The paradigm of metastasis has been significantly remodeled by the incorporation of cancer dormancy as a mechanism to explain long-term remission intervals followed by relapse. There is overall consensus on the potential impact of better understanding dormancy. Key cancer-cell autonomous and microenvironmental mechanisms might explain this biology and, in turn, the timing of metastasis. However,…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Controversy & Consensus by @JAguirreGhiso explores cancer dormancy as a mechanism to explain long remission intervals followed by relapse and discusses the development of active #clinicaltrials targeting cancer dormancy. https://t.co/0r68WWC2nj. #AACRPerspective
-
-
Mashup Score: 1A Reflection on How Carcinoma-Associated Fibroblasts Were Recognized as Active Participants of Epithelial Tumorigenesis - 4 year(s) ago
Today’s view of cancer as a systemic disease was facilitated by studies accentuating the local as well as the systemic role that non-tumorigenic cells, such as carcinoma-associated fibroblasts, play in cancer onset, development, and progression. The study highlighted in this Cancer Research Landmark was instrumental for supporting the idea that cancer is a full-body disease that depends on…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cancer is a full-body disease that depends on reciprocal interactions between cancer cells and the tumor microenvironment. In her #CRLandmark commentary, @ednacukierman highlights the work of Olumi et al on carcinoma-associated fibroblasts. https://t.co/iU0JyxkQfg https://t.co/GVYjEMdOR9
-
-
Mashup Score: 1Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers - 4 year(s) ago
The SWI/SNF chromatin-remodeling complex is frequently altered in human cancers. For example, the SWI/SNF component ARID1A is mutated in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Here, we report that ARID1A transcriptionally represses the IRE1α–XBP1 axis of the endoplasmic reticulum (ER) stress response, which confers sensitivity to…
Source: Cancer ResearchCategories: Latest Headlines, Oncologists2Tweet-
Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers | Cancer Research https://t.co/pwKigKR7ZW
-
-
Mashup Score: 2Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers - 4 year(s) ago
The SWI/SNF chromatin-remodeling complex is frequently altered in human cancers. For example, the SWI/SNF component ARID1A is mutated in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Here, we report that ARID1A transcriptionally represses the IRE1α–XBP1 axis of the endoplasmic reticulum (ER) stress response, which confers sensitivity to…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @JoeZundell: https://t.co/luJenHDIlX It’s finally done. This took 4+ years and it is far from perfect. I’m glad to have seen it through…
-
-
Mashup Score: 1Protein signatures of NK cell-mediated melanoma killing predict response to immunotherapies - 4 year(s) ago
Despite impressive advances in melanoma-directed immunotherapies, resistance is common and many patients still succumb to metastatic disease. In this context, harnessing natural killer (NK) cells, which have thus far been sidelined in the development of melanoma immunotherapy, could provide therapeutic benefits for cancer treatment. To identify molecular determinants of NK cell-mediated melanoma…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Accurate estimation of immunotherapeutic efficacy would strongly improve disease outcome. Cappello et al identify novel NK-cell-related prognostic #biomarkers that might contribute to improved and personalized melanoma-directed immunotherapies. https://t.co/1Mmate2R0h https://t.co/j0NEiPpgkE
-
-
Mashup Score: 0Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma - 4 year(s) ago
In high-grade serous ovarian carcinoma (HGSC), deleterious mutations in DNA repair gene RAD51C are established drivers of defective homologous recombination and are emerging biomarkers of PARP inhibitor (PARPi) sensitivity. RAD51C promoter methylation (me RAD51C ) is detected at similar frequencies to mutations, yet its effects on PARPi responses remain unresolved. In this study, three HGSC…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Homozygous RAD51C #PromoterMethylation is a positive predictive #biomarker for PARPi response, while a single unmethylated gene copy is sufficient to cause PARPi resistance. https://t.co/zkgdCPVRbz. @drdamienkee @SwisherLiz @genomematt @sashalouise2 https://t.co/hOlofnoCl7
-
-
Mashup Score: 3Cancer etiology and prevention: "1 + X" principle - 4 year(s) ago
Cancer was previously thought to be an inevitable aspect of human health with no effective treatments. However, the results of in-depth cancer research suggest that most types of cancer may be preventable. Therefore, a comprehensive understanding of the disparities in cancer burden caused by different risk factors is essential to inform and improve cancer prevention and control. Here we propose…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In their #ReviewArticle Liu & Dong propose a #cancer etiology and prevention principle called 1 + X, where 1 is the primary risk factor for a cancer and X contributing risk factors. https://t.co/a2HIQDVG0P https://t.co/CdI9nf1ZWj
-
-
Mashup Score: 0
Treatment-eradicated cancer subclones have been reported in leukemia and have recently been detected in solid tumors. Here we introduce Differential Subclone Eradication and Resistance (DSER) analysis, a method developed to identify molecular targets for improved therapy by direct comparison of genomic features of eradicated and resistant subclones in pre- and posttreatment samples from a patient…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Differential analysis of eradicated and resistant subclones is a new approach to identify targetable alterations and resistance mechanisms in #cancer. L1 transposon activation may be a modifiable source of genomic heterogeneity. https://t.co/1Y9M272tO8 @NykterLab https://t.co/laLFXY3cZB
-
A mathematical model successfully estimates malignant transformation-free survival and reveals a link between genetic alterations and progression, identifying precision medicine approaches for optimal treatment of gliomas. https://t.co/k9XvBcQgYM https://t.co/BVFgGYLgVQ